August 1, 2016
Pfizer Inc. has announced that it has acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C. Bamboo Therapeutics focused on developing gene therapies for treating patients with certain rare diseases related to neuromuscular conditions and the central nervous system. This acquisition will provide Pfizer with a clinical and several pre-clinical assets that complement the rare disease portfolio of the company, including an advanced recombinant Adeno-Associated Virus (rAAV) vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility that Bamboo acquired from the University of North Carolina earlier this year. In this way, this acquisition will significantly expand Pfizer’s expertise in gene therapy.
“The field of gene therapy research has made tremendous strides in recent years, and we are pleased to be able to further enhance our leadership position in this area through this transaction with Bamboo. We believe that gene therapy may hold the promise of bringing true disease modification for patients suffering from devastating diseases, and we hope to see this promise come to fruition – through new and existing in-house capabilities and potential partnership opportunities – in the years to come,” said Mikael Dolsten, President, Pfizer Worldwide Research & Development.
Gregory LaRosa, Chief Scientific Officer, Rare Disease Research Unit, Pfizer, said: “We believe Bamboo’s industry leading capabilities in rAAV vector design and manufacturing complement Pfizer’s rare disease strategy and help advance Pfizer’s mission to deliver life-changing innovation to patients with the greatest needs. Bringing together Pfizer and Bamboo colleagues’ deep scientific understanding of both rAAV biology and complex biologic manufacturing will help position us for success in this area.”